Axonics, Inc. (AXNX)
Largest Insider Buys in Sector
AXNX Stock Price History Chart
AXNX Stock Performance
About Axonics, Inc.
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and …
Insider Activity of Axonics, Inc.
Over the last 12 months, insiders at Axonics, Inc. have bought $0 and sold $7.4M worth of Axonics, Inc. stock.
On average, over the past 5 years, insiders at Axonics, Inc. have bought $0 and sold $41.73M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,000 shares for transaction amount of $212,878 was made by COHEN RAYMOND W () on 2019‑08‑06.
List of Insider Buy and Sell Transactions, Axonics, Inc.
| 2024-10-02 | Sale | Chief Financial Officer | 2,961 0.0058% | $69.41 | $205,512 | +1.15% | ||
| 2024-01-31 | Sale | Chief Executive Officer | 35,161 0.0691% | $67.74 | $2.38M | +0.10% | ||
| 2024-01-31 | Sale | EVP, Chief Mktg/Strtgy Officer | 15,899 0.0313% | $67.74 | $1.08M | +0.10% | ||
| 2024-01-31 | Sale | Chief Commercial Officer | 16,615 0.0327% | $67.74 | $1.13M | +0.10% | ||
| 2024-01-31 | Sale | Chief Financial Officer | 3,489 0.0069% | $67.74 | $236,331 | +0.10% | ||
| 2024-01-31 | Sale | Chief Medical Officer | 11,288 0.0222% | $67.74 | $764,603 | +0.10% | ||
| 2024-01-08 | Sale | Chief Medical Officer | 15,999 0.0316% | $69.00 | $1.1M | -1.52% | ||
| 2023-12-28 | Sale | Chief Medical Officer | 7,051 0.0138% | $63.28 | $446,177 | +6.54% | ||
| 2023-12-26 | Sale | Chief Medical Officer | 949 0.0019% | $63.00 | $59,787 | +9.08% | ||
| 2023-09-29 | Sale | President & CFO | 7,675 0.0154% | $56.87 | $436,490 | +20.37% | ||
| 2023-08-15 | Sale | Chief Commercial Officer | 14,769 0.0292% | $62.34 | $920,671 | +7.34% | ||
| 2023-07-28 | Sale | Chief Commercial Officer | 1,500 0.0035% | $62.01 | $93,021 | +9.85% | ||
| 2023-05-26 | Sale | President & CFO | 7,999 0.0168% | $49.46 | $395,646 | +21.49% | ||
| 2023-04-21 | Sale | President & CFO | 20,000 0.0412% | $60.21 | $1.2M | -4.41% | ||
| 2023-04-20 | Sale | President & CFO | 2,001 0.0042% | $60.01 | $120,073 | -3.28% | ||
| 2023-03-31 | Sale | 15,000 0.0313% | $55.27 | $829,103 | +5.04% | |||
| 2023-02-21 | Sale | 19,929 0.0404% | $56.27 | $1.12M | -0.77% | |||
| 2023-02-21 | Sale | 23,321 0.0473% | $56.31 | $1.31M | -0.77% | |||
| 2023-02-01 | Sale | 8,117 0.0167% | $60.93 | $494,578 | -7.34% | |||
| 2023-02-01 | Sale | 5,075 0.0104% | $60.93 | $309,225 | -7.34% |
Insider Historical Profitability
| COHEN RAYMOND W | Chief Executive Officer | 188835 0.3694% | $70.48 | 1 | 24 | +2.21% |
| Gilde Healthcare Holding B.V. | 10 percent owner | 3133332 6.1296% | $70.48 | 1 | 0 | +49.27% |
| Wisniewski Raphael | 2957461 5.7855% | $70.48 | 1 | 3 | +49.27% | |
| Andera Partners | 2957461 5.7855% | $70.48 | 1 | 3 | +49.27% | |
| Longitude Capital Partners III, LLC | 10 percent owner | 2933333 5.7383% | $70.48 | 1 | 0 | +49.27% |
Institutional Investor Ownership
| The Vanguard Group | $347.74M | 9.88 | 5.04M | -4.16% | -$15.1M | 0.01 | |
| BlackRock | $295.6M | 8.4 | 4.29M | +2.29% | +$6.63M | 0.01 | |
| Alpine Associates Management Inc | $125.16M | 3.56 | 1.81M | New | +$125.16M | 0.33 | |
| Fil Ltd | $118.59M | 3.37 | 1.72M | New | +$118.59M | 0.12 | |
| Mackenzie Financial Corp | $87.41M | 2.48 | 1.27M | +1.39% | +$1.2M | 0.12 |